From Recognition to Commitment: Why I Compared Diagnostics Across National Policy

I have been interested for some time in a deceptively simple question: how does a country build diagnostics sovereignty?

I have written about the question at book length, particularly in relation to the Gulf countries. But as I tried to refine the idea into more specific and actionable proposals, I repeatedly encountered a problem that had to be addressed first.

Before proposing where countries should go, I needed to understand where they were starting from.

How do governments currently account for diagnostics in their health-security, preparedness, industrial, genomic and sovereignty policies? What exactly do they recognise as a diagnostic capability? Who is expected to deliver it? What resources and instruments are attached to it? And what evidence would allow an external observer to determine whether the promised capability actually exists?

These questions led me beyond individual examples and towards a more systematic comparison.

What I examined

The resulting working paper, From Recognition to Commitment: A Comparative Review of Diagnostic Policy Standing and Implementation Traceability, examines twenty official policy texts across fifteen national and regional entities. World Health Organization instruments provide the global context.

The comparison includes policies concerned with:

• pandemic and biological preparedness;
• medical countermeasures;
• medical technology and industrial capability;
• health sovereignty and resilience;
• genomics, health data and precision health.

This is not a ranking of countries, nor an attempt to determine which jurisdictions are diagnostically sovereign. Public policy documents cannot establish that on their own. The narrower objective was to understand the position assigned to diagnostics within different kinds of policy and to trace the distance between four evidentiary states:

1. Diagnostic recognition: diagnostics are named and assigned a place within the policy.
2. Attributable commitment: that recognition is connected to an instrument, responsible actor, resource route, deliverable or timetable.
3. Operational traceability: an external reader can identify what should happen, who should act and where evidence of implementation ought to appear.
4. Functional demonstration: evidence shows that the intended diagnostic capability works in practice.

What the comparison revealed

The principal finding is not that diagnostics are absent from policy. They are widely present, but they do not appear as a single, coherent policy object.

Preparedness policies tend to treat diagnostics as instruments for rapid detection, surge testing and emergency response. Industrial policies focus on research, production, commercialisation and market development. Genomic strategies emphasise sequencing, population representation, data and interpretation. Health-service policies focus on laboratory networks, clinical pathways and access. Sovereignty-oriented agendas connect some combination of production, procurement, finance, regulation and regional capability.

Each policy family makes particular capabilities and dependencies visible. Each also leaves others outside its immediate field of view.

Recognition is therefore more common than a complete, attributable commitment. Policies frequently identify ministries, agencies, laboratories, funders and partners, but less often make clear who is ultimately answerable for maintaining a diagnostic function in practice.

Financial commitments are usually embedded within broader programmes for medical countermeasures, medical devices, genomics, research or industrial development. These may provide legitimate routes for diagnostic investment, but their total value cannot be treated as diagnostic expenditure.

Publicly visible monitoring also tends to concentrate on intermediate outputs: programmes launched, facilities opened, agreements signed, laboratories designated, samples collected or nominal capacity created. These are meaningful achievements, but they do not necessarily demonstrate equipment uptime, consumable continuity, clinically appropriate turnaround, affordability, equitable access or performance during disruption.

Maintenance emerged as a particularly persistent weakness. Instruments, platforms and laboratories appear throughout the documents. Service engineers, spare parts, calibration materials, software support, licences and restoration standards appear far less consistently.

Why this matters

The comparison reinforced a conclusion that has become central to my thinking: diagnostic sovereignty cannot be inferred from the number of factories a country has built, the percentage of local content it reports, the genomic data it stores domestically or the scale of an announced investment.

Those may all contribute to sovereignty. None independently establishes it.

The relevant question is whether a health system can continue to generate and use reliable, timely and appropriate diagnostic information for its population, during ordinary conditions and disruption, and whether the critical dependencies required to sustain that function are understood and effectively governed.

Domestic production may be part of the answer. So may regional capability, diversified supply, trusted relationships, technology transfer, shared reference laboratories, strategic reserves and credible substitution arrangements. Sovereignty is not the same as autarky.

Why Version 0.99?

I have published this as Version 0.99 because it is a working paper rather than a final statement.

The paper is not peer reviewed, does not represent the position of any institution and does not claim to provide a validated measure of diagnostic sovereignty. Its purpose is to make the analysis visible, citable and open to correction.

I would particularly welcome:

• important policy documents or sources I may have missed;
• corrections to the interpretation of individual policies;
• criticism of the comparative method;
• alternative explanations for the patterns identified;
• examples of implementation evidence that connect policy commitments to functioning diagnostic capability.

The supplementary source and extraction register is published with the paper so that the underlying document choices and interpretative decisions can be examined.